Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
Subscribe To Our Newsletter & Stay Updated
